Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

July 2023

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 JULY 2023

- Adalimumab (Humira – alternative brand) (HumiraPen) inj 40 mg per 0.4 ml prefilled pen – new listing
- Adalimumab (Humira – alternative brand) inj 40 mg per 0.8 ml pen (HumiraPen) and inj 40 mg per 0.8 ml syringe (Humira) – to be delisted 1 March 2024
- Ambrisentan (Ambrisentan Viatris) tab 5 mg and 10 mg – price decrease and addition of PSS
- Ambrisentan tab 5 mg (Ambrisentan Mylan) and 10 mg (Mylan) to be delisted 1 December 2023.
- Amino acid formula (without phenylalanine) (PKU sphere20 Red Berry, Vanilla and Chocolate) powder 20 g protein, 6.3 g carbohydrate per 35 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU sphere20 Banana) powder 20 g protein, 6.7 g carbohydrate per 35 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU sphere20 Lemon) powder 20 g protein, 6.0 g carbohydrate per 35 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU Red Berry, Vanilla, Chocolate, Banana and Lemon) to be delisted 1 January 2024.
- Amisulpride (Sulprix) tab 100 mg, 200 mg and 400 mg – price increase
- Anastrazole (Anatrole) tab 1 mg – price decrease and addition of PSS
- Atezolizumab (Tecentriq) inj 60 mg per ml, 20 ml vial – amended restriction criteria
- Bedaquiline (Sirturo) tab 100 mg, 24 and 188 tab pack – new listing
- Betahistine hydrochloride (Serc) tab 16 mg – price decrease and addition of PSS
- Bicalutamide (Binarex) tab 50 mg – price decrease and addition of PSS
- Candesartan cilexetil with hydrochloride tab 16 mg with hydrochlorothiazide 12.5 mg (APO-Candesartan HCTZ 16/12.5) and tab 32 mg with hydrochlorothiazide 12.5 mg (APO-Candesartan HCTZ 32/12.5) – new listing
- Cefotaxime (DBL Cefotaxime) inj 1 g vial – price decrease and addition of PSS
- Ceftazidime (Ceftazidim-AFT) inj 1 g vial – to be delisted 1 December 2023
- Ceftazidime (Ceftazidime Kabi) inj 1 g vial – new listing and addition of PSS
- Cefuroxime (Zinnat) tab 250 mg – delisted 1 July 2023
- Cefuroxime tab 250 mg – new listing
- Ciprofloxacin (Ciprofloxacin Kabi) inj 2 mg per ml, 100 ml bottle – amended presentation description
- Ciprofloxacin (Viatris) inj 2 mg per ml, 100 ml bag – delisted 1 July 2023

Summary of decisions – effective 1 July 2023 (continued)

- Darunavir (Darunavir Mylan) tab 400 mg, Pharmacodes 2591286 and 2595486 – to be delisted 1 January 2024
- Docetaxel (DBL Docetaxel) inj 10 mg per ml, 8 ml vial – price decrease and addition of PSS
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28) – amended presentation description
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28) – amended presentation description
- Ezetimibe (Ezetimibe Sandoz) tab 10 mg, Pharmacode 2545861 – price decrease and addition of PSS
- Ezetimibe (Ezetimibe Sandoz) tab 10 mg, Pharmacode 2536129 – to be delisted 1 December 2023
- Finasteride (Ricit) tab 5 mg – price decrease and addition of PSS
- Flecainide acetate (Flecainide BNM) tab 50 mg – addition of PSS
- Fluconazole (Mylan) cap 50 mg – price increase and addition of PSS
- Fluconazole (Mylan) cap 150 mg and 200 mg – price decrease and addition of PSS
- Folic acid (Folic Acid Mylan) tab 5 mg – to be delisted 1 January 2024
- Hydroxyurea [Hydrocycarbamide] (Devatis) cap 500 mg – price decrease and addition of PSS
- Hyoscine butylbromide (Buscopan) inj 20 mg, 1 ml ampoule – to be delisted 1 December 2023
- Hyoscine butylbromide (Spazmol) inj 20 mg, 1 ml ampoule – new listing and addition of PSS
- Imatinib mesilate (Glivec) tab 100 mg – to be delisted 1 December 2023
- Imatinib mesilate (Imatinib-Rex) cap 100 mg and 400 mg – price decrease and addition of PSS
- Influenza vaccine (FluQuadri (2023 Formulation)) inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) – new listing
- Influenza vaccine (FluQuadri (2023 Formulation)) inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) – to be delisted 1 January 2024
- Itraconazole (Itrazole) cap 100 mg – price increase
- Lamotrigine (Logem) tab dispersible 25 mg, 50 mg and 100 mg – price increase
- Leflunomide (Arava) tab 10 mg and 20 mg – addition of PSS
- Levonorgestrel (Jadelle) subdermal implant (2 x 75 mg rods) – addition of PSS

Summary of decisions – effective 1 July 2023 (continued)

- Macrogol 3350 with ascorbic acid, potassium chloride, sodium chloride and citric acid with magnesium oxide and sodium picosulfate (e.g. Prepkit-C) powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) – delisted 1 July 2023
- Mebeverine hydrochloride (Colofac) tab 135 mg – price decrease and addition of PSS
- Melphalan (Melpha) inj 50 mg vial – price decrease and addition of PSS
- Methotrexate (Methotrexate Ebewe) inj 100 mg per ml, 50 ml vial – price decrease and addition of PSS
- Metronidazole (Baxter) inj 5 mg per ml, 100 ml bag – price decrease and addition of PSS
- Montelukast (Montelukast Mylan) tab 5 mg – removal of PSS and to be delisted 1 January 2024
- Montelukast (Montelukast Viatris) tab 5 mg – addition of PSS
- Naltrexone hydrochloride (Naltracord) tab 50 mg – price decrease and addition of PSS
- Nifedipine (Tensipine MR10) tab long-acting 10 mg – addition of restriction criteria
- Nitrofurantoin (Macrobid) cap modified-release 100 mg – price decrease and addition of PSS
- Pembrolizumab (Keytruda) inj 25 mg per ml, 4 ml vial – amended restriction criteria
- Phenobarbitone (Noumed Phenobarbitone) tab 30 mg – new listing and addition of PSS
- Phenobarbitone (PSM) tab 30 mg – to be delisted 1 December 2023
- Pravastatin (Pravastatin Mylan) tab 20 mg – to be delisted 1 January 2024
- Rifampicin (Rifadin) cap 150 mg, cap 300 mg, oral liq 100 mg per ml, 5 ml and inj 600 mg vial – addition of PSS
- Rituximab (Riximyo) (Riximyo) inj 10 mg per ml, 10 ml vial and 50 ml vial – amended restriction criteria
- Rivaroxaban (Xarelto) tab 10 mg, 15 mg and 20 mg – price decrease and addition of PSS
- Rosuvastatin (Rosuvastatin Viatris) tab 5 mg, 10 mg, 20 mg and 40 mg, 30 bottle pack – new Pharmacode listing and addition of PSS
- Rosuvastatin (Rosuvastatin Viatris) tab 5 mg, 10 mg, 20 mg and 40 mg, 30 blister pack– price decrease and to be delisted 1 December 2023
- Tacrolimus (Zematop) oint 0.1%, 30 g – addition of PSS

Summary of decisions – effective 1 July 2023 (continued)

- Tamoxifen citrate (Tamoxifen Sandoz) tab 10 mg – addition of PSS
- Tamoxifen citrate (Tamoxifen Sandoz) tab 20 mg – price decrease and addition of PSS
- Terlipressin (Glyressin) inj 0.1 mg per ml, 8.5 ml ampoule – delisted 1 July 2023
- Tobramycin (Tobramycin BNM) solution for inhalation 60 mg per 5 ml – addition of PSS
- Tobramycin (Tobramycin Mylan) inj 40 mg per ml, 2 ml vial – removal of PSS and to be delisted 1 January 2024
- Tobramycin (Viatris) inj 40 mg per ml, 2 ml vial – addition of PSS
- Tramadol hydrochloride inj 50 mg per ml, 1 ml ampoule (Tramal 50) and 2 ml ampoule (Tramal 100) – new Pharmacode listing
- Tramadol hydrochloride tab sustained-release 100 mg (Tramal SR 100), 150 mg (Tramal SR 150) and 200 mg (Tramal SR 200) – new Pharmacode listing
- Venlafaxine (Enlafax XR) cap 37.5 mg, 75 mg and 150 mg – price increase
- Zidovudine [AZT] with lamivudine (Alphapharm) tab 300 mg with lamivudine 150 mg – price increase

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 July 2023

ALIMENTARY TRACT AND METABOLISM

7 HYOSCINE BUTYLBROMIDE (new listing and addition of PSS)
Inj 20 mg, 1 ml ampoule – **5% DV Dec-23 to 2026** ..... 1.91 5 **Spazmol**
Note – Buscopan inj 20 mg, 1 ml ampoule to be delisted 1 December 2023.

7 MEBEVERINE HYDROCHLORIDE (↓ price and addition of PSS)
Tab 135 mg – **5% DV Dec-23 to 2026** ..... 8.50 90 **Colofac**

14 MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE (delisting)
Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) *e.g. Prepkit-C*
Note – Prepkit-C powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) delisted on 1 July 2023.

BLOOD AND BLOOD FORMING ORGANS

30 FOLIC ACID (delisting)
Tab 5 mg ..... 5.82 100 Folic Acid Mylan
Note – Folic Acid Mylan tab 5 mg to be delisted from 1 January 2024.

37 RIVAROXABAN (↓ price and addition of PSS)
Tab 10 mg – **5% DV Dec-23 to 2026** ..... 15.60 30 **Xarelto**
Tab 15 mg – **5% DV Dec-23 to 2026** ..... 14.56 28 **Xarelto**
Tab 20 mg – **5% DV Dec-23 to 2026** ..... 14.56 28 **Xarelto**

CARDIOVASCULAR SYSTEM

44 CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE (new listing)
Tab 16 mg with hydrochlorothiazide 12.5 mg ..... 4.10 30 APO-Candesartan HCTZ 16/12.5
Tab 32 mg with hydrochlorothiazide 12.5 mg ..... 5.25 30 APO-Candesartan HCTZ 32/12.5

46 FLECAINIDE ACETATE (addition of PSS)
Tab 50 mg – **5% DV Dec-23 to 2026** ..... 19.95 60 **Flecainide BNM**

49 NIFEDIPINE (addition of restriction criteria)
➔ Tab long-acting 10 mg
– **Restricted: For continuation only** ..... 18.80 56 Tensipine MR10

Changes to Section H Part II – effective 1 July 2023 (continued)

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer
52	PRAVASTATIN (delisting)			
	Tab 20 mg	2.11	28	Pravastatin Mylan
	Note – Pravastatin Mylan tab 20 mg to be delisted from 1 January 2024.			
52	ROSUVASTATIN (new listing and addition of PSS)			
	➔ Tab 5 mg – **5% DV Dec-23 to 2026**	1.29	30	**Rosuvastatin Viatris**
	➔ Tab 10 mg – **5% DV Dec-23 to 2026**	1.69	30	**Rosuvastatin Viatris**
	➔ Tab 20 mg – **5% DV Dec-23 to 2026**	2.71	30	**Rosuvastatin Viatris**
	➔ Tab 40 mg – **5% DV Dec-23 to 2026**	4.55	30	**Rosuvastatin Viatris**
	Note – These are the listing of new Pharmacodes 2651130, 2651149, 2651157 and 2651165 respectively.			
52	ROSUVASTATIN (↓ price and delisting)			
	➔ Tab 5 mg	1.29	30	Rosuvastatin Viatris
	➔ Tab 10 mg	1.69	30	Rosuvastatin Viatris
	➔ Tab 20 mg	2.71	30	Rosuvastatin Viatris
	➔ Tab 40 mg	4.55	30	Rosuvastatin Viatris
	Note – These price changes are for the blister pack with Pharmacodes 2616742, 2616750, 2616769, 2616777 respectively. Rosuvastatin Viatris tab 5 mg (2616742), 10 mg (2616750), 20 mg (2616769) and 40 mg (2616777) to be delisted from 1 December 2023.			
53	EZETIMIBE (↓ price and addition of PSS)			
	➔ Tab 10 mg – **5% DV Dec-23 to 2026**	1.76	30	**Ezetimibe Sandoz**
	Note – this price decrease applies to Pharmacode 2545861. Ezetimibe Sandoz tab 10 mg, Pharmacode 2536129 to be delisted from 1 December 2023.			
55	AMBRISENTAN (↓ price, addition of PSS and delisting)			
	➔ Tab 5 mg – **5% DV Dec-23 to 2026**	200.00	30	**Ambrisentan Viatris**
	➔ Tab 10 mg – **5% DV Dec-23 to 2026**	200.00	30	**Ambrisentan Viatris**
	Note – Ambrisentan Mylan tab 5 mg and Mylan tab 10 mg to be delisted from 1 December 2023.			

DERMATOLOGICALS

64	TACROLIMUS (addition of PSS)			
	➔ Oint 0.1% – **5% DV Dec-23 to 2026**	33.00	30 g	**Zematop**

GENITO-URINARY SYSTEM

67	LEVONORGESTREL (addition of PSS)			
	Subdermal implant (2 × 75 mg rods)			
	– **5% DV Dec-23 to 2026**	106.92	1	**Jadelle**
68	FINASTERIDE (↓ price and addition of PSS)			
	Tab 5 mg – **5% DV Dec-23 to 2026**	4.79	100	**Ricit**

Changes to Section H Part II – effective 1 July 2023 (continued)

INFECTIONS

79 TERLIPRESSIN (delisting)
Inj 0.1 mg per ml, 8.5 ml ampoule ..... 450.00 5 Glypressin
Note – Glypressin inj 0.1 mg per ml, 8.5 ml ampoule delisted on 1 July 2023.

80 TOBRAMYCIN (removal of PSS and delisting)
➔ Inj 40 mg per ml, 2 ml vial
– 5% DV Jan-22 to ~~2024~~ **30/06/2023** ..... 18.50 5 **Tobramycin Mylan**
Note – Tobramycin Mylan inj 40 mg per ml, 2 ml vial to be delisted from 1 January 2024.

80 TOBRAMYCIN (addition of PSS)
➔ Inj 40 mg per ml, 2 ml vial – **5% DV Jul-23 to 2024**..... 18.50 5 **Viatris**

80 TOBRAMYCIN (addition of PSS)
➔ Solution for inhalation 60 mg per ml, 5 ml
– **5% DV Dec-23 to 2026**..... 395.00 56 dose **Tobramycin BNM**

81 CEFUROXIME (delisting)
Tab 250 mg..... 45.93 50 Zinnat
Note – Zinnat tab 250 mg delisted on 1 July 2023.

81 CEFUROXIME (new listing)
Tab 250 mg

81 CEFOTAXIME (↓ price and addition of PSS)
Inj 1 g vial – **5% DV Dec-23 to 2026**..... 38.98 10 **DBL Cefotaxime**

81 CEFTAZIDIME (new listing and addition of PSS)
➔ Inj 1 g vial – **5% DV Dec-23 to 2026**..... 25.80 10 **Ceftazidime Kabi**
Note – Ceftazidime-AFT inj 1 g vial to be delisted from 1 December 2023.

85 CIPROFLOXACIN (delisting)
➔ Inj 2 mg per ml, 100 ml bag..... 148.00 10 Viatris
Note – Viatris inj 2 mg per ml, 100 ml bag to be delisted from 1 July 2023.

85 CIPROFLOXACIN (amended presentation description)
➔ Inj 2 mg per ml, 100 ml ~~bag~~ **bottle**..... 125.00 10 Ciprofloxacin Kabi

87 NITROFURANTOIN (↓ price and addition of PSS)
Cap modified-release 100 mg – **5% DV Dec-23 to 2026** ..... 81.20 100 **Macrobid**

88 FLUCONAZOLE (↓ price and addition of PSS)
➔ Cap 150 mg – **5% DV Dec-23 to 2026** ..... 0.45 1 **Mylan**
➔ Cap 200 mg – **5% DV Dec-23 to 2026** ..... 8.90 28 **Mylan**

88 FLUCONAZOLE (↑ price and addition of PSS)
➔ Cap 50 mg – **5% DV Dec-23 to 2026** ..... 4.10 28 **Mylan**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 July 2023 (continued)

88 ITRACONAZOLE (↑ price)

➔ Cap 100 mg	6.83	15	Itrazole

90 BEDAQUILINE (new listing)

➔ Tab 100 mg	3,084.51	24	Sirturo
	24,162.00	188	Sirturo

Restricted
Initiation – multi-drug resistant tuberculosis.
Limited to 6 months treatment
Both:
1 The person has multi-drug resistant tuberculosis (MDR-TB); and
2 Manatū Hauora - Ministry of Health's Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen.
Note – Sirturo tab 100 mg, 188 tab pack to be delisted from 1 July 2024.

91 RIFAMPICIN (addition of PSS)

➔ Cap 150 mg – **5% DV Dec-23 to 2026**	58.54	100	**Rifadin**
➔ Cap 300 mg – **5% DV Dec-23 to 2026**	122.06	100	**Rifadin**
➔ Oral liq 100 mg per 5 ml – **5% DV Dec-23 to 2026**	12.60	60 ml	**Rifadin**
➔ Inj 600 mg vial – **5% DV Dec-23 to 2026**	134.98	1	**Rifadin**

92 METRONIDAZOLE (↓ price and addition of PSS)

Inj 5 mg per ml, 100 ml bag – **5% DV Dec-23 to 2026**	18.00	10	**Baxter**

95 ZIDOVUDINE [AZT] WITH LAMIVUDINE (↑ price)

➔ Tab 300 mg with lamivudine 150 mg	92.40	60	Alphapharm

95 DARUNAVIR (delisting)

➔ Tab 400 mg	132.00	60	Darunavir Mylan

Note – Darunavir Mylan tab 400 mg Pharmacodes 2591286 and 2595486 to be delisted from 1 January 2024.

MUSCULOSKELETAL SYSTEM

103 LEFLUNOMIDE (addition of PSS)

Tab 10 mg – **5% DV Dec-23 to 2026**	6.00	30	**Arava**
Tab 20 mg – **5% DV Dec-23 to 2026**	6.00	30	**Arava**

NERVOUS SYSTEM

117 TRAMADOL HYDROCHLORIDE (new listing)

Tab sustained-release 100 mg	1.95	20	Tramal SR 100
Tab sustained-release 150 mg	2.95	20	Tramal SR 150
Tab sustained-release 200 mg	3.80	20	Tramal SR 200
Inj 50 mg per ml, 1 ml ampoule	10.00	5	Tramal 50
Inj 50 mg per ml, 2 ml ampoule	9.00	5	Tramal 100

Note – These are the listing of new Pharmacodes 2650959, 2650967, 2650975, 2650940 and 2650932 respectively.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 July 2023 (continued)

118 VENLAFAXINE (↑ price)

Cap 37.5 mg	8.29	84	Enlafax XR
Cap 75 mg	10.32	84	Enlafax XR
Cap 150 mg	13.95	84	Enlafax XR

119 PHENOBARBITONE (new listing and addition of PSS)

Tab 30 mg – **5% DV Dec-23 to 2025**	398.50	500	**Noumed Phenobarbitone**

Note – PSM tab 30 mg to be delisted from 1 December 2023.

120 LAMOTRIGINE (↑ price)

Tab dispersible 25 mg	4.20	56	Logem
Tab dispersible 50 mg	5.11	56	Logem
Tab dispersible 100 mg	6.75	56	Logem

122 BETAHISTINE DIHYDROCHLORIDE (↓ price and addition of PSS)

Tab 16 mg – **5% DV Dec-23 to 2026**	3.70	100	**Serc**

123 AMISULPRIDE (↑ price)

Tab 100 mg	7.21	30	Sulprix
Tab 200 mg	20.94	60	Sulprix
Tab 400 mg	38.71	60	Sulprix

134 NALTREXONE HYDROCHLORIDE (↓ price and addition of PSS)

➔ Tab 50 mg – **5% DV Dec-23 to 2026**	83.33	30	**Naltraccord**

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137 MELPHALAN (↓ price and addition of PSS)

Inj 50 mg vial – **5% DV Dec-23 to 2026**	48.25	1	**Melpha**

139 METHOTREXATE (↓ price and addition of PSS)

Inj 100 mg per ml, 50 ml vial – **5% DV Dec-23 to 2026**	67.99	1	**Methotrexate Ebewe**

141 HYDROXYUREA [HYDROXYCARBAMIDE] (↓ price and addition of PSS)

Cap 500 mg – **5% DV Dec-23 to 2026**	20.72	100	**Devatis**

149 IMATINIB MESILATE (↓ price and addition of PSS)

Cap 100 mg – **5% DV Dec-23 to 2026**	44.93	60	**Imatinib-Rex**
Cap 400 mg – **5% DV Dec-23 to 2026**	69.76	30	**Imatinib-Rex**

Note – Glivec tab 100 mg to be delisted from 1 December 2023.

153 DOCETAXEL (↓ price and addition of PSS)

Inj 10 mg per ml, 8 ml vial – **5% DV Dec-23 to 2026**	24.91	1	**DBL Docetaxel**

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 July 2023 (continued)

155 BICALUTAMIDE (↓ price and addition of PSS)
Tab 50 mg – **5% DV Dec-23 to 2026** ..... 4.18 28 **Binarex**

157 TAMOXIFEN CITRATE (addition of PSS)
Tab 10 mg – **5% DV Dec-23 to 2026** ..... 15.00 60 **Tamoxifen Sandoz**

157 TAMOXIFEN CITRATE (↓ price and addition of PSS)
Tab 20 mg – **5% DV Dec-23 to 2026** ..... 5.32 60 **Tamoxifen Sandoz**

157 ANASTROZOLE (↓ price and addition of PSS)
Tab 1 mg – **5% DV Dec-23 to 2026** ..... 4.39 30 **Anatrole**

174 ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) (new listing)
➔ Inj 40 mg per 0.4 ml prefilled pen ..... 1,599.96 2 HumiraPen
Note – Adalimumab inj 40 mg per 0.8 ml syringe (Humira) and pen (HumiraPen) to be delisted from 1 March 2024.

200 RITUXIMAB (RIXIMYO) (amended restriction criteria – new criteria shown only)
➔ Inj 10 mg per ml, 10 ml vial ..... 275.33 2 Riximyo
➔ Inj 10 mg per ml, 50 ml vial ..... 688.20 1 Riximyo

Restricted
Initiation – immunoglobulin G4-related disease (IgG4-RD*)
Re-assessment required after 6 weeks
All of the following:
1 Patient has confirmed diagnosis of IgG4-RD*; and
2 Either:
2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or
2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and
3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart.
Note: Indications marked with * are unapproved indications

Continuation – immunoglobulin G4-related disease (IgG4-RD*)
Re-assessment required after 12 months
All of the following:
1 Either:
1.1 Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or
1.2 Patient is receiving maintenance treatment for IgG4-RD*; and
2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and
3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.
Note: Indications marked with * are unapproved indications

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 July 2023 (continued)

222 ATEZOLIZUMAB (amended restriction criteria)

➔ Inj 60 mg per ml, 20 ml vial ..... 9,503.00 1 Tecentriq

Restricted
Initiation – non-small cell lung cancer second line monotherapy
Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist
Re-assessment required after 4 months
~~Either:~~
~~1 Patient is currently on treatment with atezolizumab and met all remaining criteria below prior to commencing treatment; or~~
~~2~~ All of the following:
- ~~2.1~~ **1** Patient has locally advanced or metastatic non-small cell lung cancer; and
- ~~2.2~~ **2** Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- ~~2.3~~ **3** There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- ~~2.4~~ **4** Patient has an ECOG 0-2; and
- ~~2.5~~ **5** Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- ~~2.6~~ **6** Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and
- ~~2.7~~ **7** Baseline measurement of overall tumour burden is documented clinically and radiologically.

225 PEMBROLIZUMAB (amended restriction criteria – new criteria shown only)

➔ Inj 25 mg per ml, 4 ml vial ..... 4,680.00 1 Keytruda

Restricted
Initiation – non-small cell lung cancer first-line monotherapy
Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist
Re-assessment required after 4 months
~~Either:~~
~~1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or~~
~~2~~ All of the following:
- ~~2.1~~ **1** Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- ~~2.2~~ **2** Patient has not had chemotherapy for their disease in the palliative setting; and
- ~~2.3~~ **3** Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- ~~2.4~~ **4** There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- ~~2.5~~ **5** Pembrolizumab to be used as monotherapy; and
- ~~2.6~~ **6** Either:
  - ~~2.6.1~~ **6.1** There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or
  - ~~2.6.2~~ **6.2** Both:
    - ~~2.6.2.1~~ **6.2.1** There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and
    - ~~2.6.2.2~~ **6.2.2** Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and
- ~~2.7~~ **7** Patient has an ECOG 0-2; and
- ~~2.8~~ **8** Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and
- ~~2.9~~ **9** Baseline measurement of overall tumour burden is documented clinically and radiologically.

continued...

Changes to Section H Part II – effective 1 July 2023 (continued)

continued...

Initiation – non-small cell lung cancer first-line combination therapy
Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist
Re-assessment required after 4 months
~~Either:~~
~~1 Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment; or~~
~~2~~ All of the following:
- ~~2.1~~ **1** Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- ~~2.2~~ **2** The patient has not had chemotherapy for their disease in the palliative setting; and
- ~~2.3~~ **3** Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- ~~2.4~~ **4** There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- ~~2.5~~ **5** Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- ~~2.6~~ **6** Patient has an ECOG 0-2; and
- ~~2.7~~ **7** Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 12 weeks; and
- ~~2.8~~ **8** Baseline measurement of overall tumour burden is documented clinically and radiologically.

RESPIRATORY SYSTEM AND ALLERGIES

237	MONTELUKAST (removal of PSS and delisting)			
	Tab 5 mg – 5% DV Dec-22 to ~~2025~~ **30/06/2023**	3.10	28	Montelukast Mylan
	Note – Montelukast Mylan tab 5 mg to be delisted from 1 January 2024.			
237	MONTELUKAST (addition of PSS)			
	Tab 5 mg – **5% DV Jul-23 to 2025**	3.10	28	**Montelukast Viatris**
239	ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR (amended presentation)			
	➔ Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg **(56)** and ivacaftor 75 mg **(28)**	27,647.39	84	Trikafta
	➔ Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg **(56)** and ivacaftor 150 mg **(28)**	27,647.39	84	Trikafta

Changes to Section H Part II – effective 1 July 2023 (continued)

SPECIAL FOODS

275 AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing)
➔ Powder 20 g protein, 6.3 g carbohydrate
per 35 g sachet ..... 930.00 30 PKU sphere20 Red Berry
PKU sphere20 Vanilla
PKU sphere20 Chocolate
Note – PKU sphere20 Red Berry, Vanilla and Chocolate powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be delisted 1 January 2024.

275 AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing)
➔ Powder 20 g protein, 6.7 g carbohydrate
per 35 g sachet ..... 930.00 30 PKU sphere20 Banana
Note – PKU sphere20 Banana powder 20 g protein, 6.7 g carbohydrate per 35 g sachet to be delisted 1 January 2024.

275 AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing)
➔ Powder 20 g protein, 6.0 g carbohydrate
per 34 g sachet ..... 930.00 30 PKU sphere20 Lemon
Note – PKU sphere20 Lemon powder 20 g protein, 6.0 g carbohydrate per 35 g sachet to be delisted 1 January 2024.

VACCINES

282 INFLUENZA VACCINE (new listing)
➔ Inj 60 mcg in 0.5 ml syringe
(paediatric quadrivalent vaccine) ..... 50.00 5 FluQuadri (2023 Formulation)
Restricted
Initiation – children 6 months to 35 months of age
Children 6 months to 35 months of age (inclusive) from 1 July 2023 to 31 December 2023.
Note – FluQuadri (2023 Formulation) to be delisted 1 January 2024.

Index
Pharmaceuticals and brands

Index
Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government